Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals CoSZSE:301201 +2.26%75 PS Ratio is 12.53 as of Jul. 15, 2026, which is 14% above its 10-year median of 11.01. GuruFocus rates SZSE:301201 with a GF Score™ of 75/100 and a GF Value™ of ¥30.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Chengda Pharmaceuticals Co ranks worse than 90.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Chengda Pharmaceuticals Co's share price is ¥37.94.
Chengda Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.03. Hence, Chengda Pharmaceuticals Co's PS Ratio for today is 12.53.
The historical rank and industry rank for Chengda Pharmaceuticals Co's PS Ratio or its related term are showing as below:
SZSE:301201'
s PS Ratio Range Over the Past 10 Years
Min: 6.3 Med: 11.01 Max: 23.93
Current: 12.52
During the past 12 years, Chengda Pharmaceuticals Co's highest PS Ratio was 23.93. The lowest was 6.30. And the median was 11.01.
SZSE:301201's PS Ratio is ranked worse than 90.05% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs SZSE:301201: 12.52
Chengda Pharmaceuticals Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Chengda Pharmaceuticals Co was 48.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.20% per year.
During the past 12 years, Chengda Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 24.10% per year. The lowest was -63.60% per year. And the median was -0.40% per year.
Back to Basics: PS Ratio
Chengda Pharmaceuticals Co (SZSE:301201) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Chengda Pharmaceuticals Co PS Ratio Related Terms
Chengda Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Chengda Pharmaceuticals Co's Share Price of today is ¥37.94. Chengda Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Chengda Pharmaceuticals Co (SZSE:301201) has a PS Ratio of 12.53 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chengda Pharmaceuticals Co and its competitors. This is 14% above median its historical median of 11.01. Over the past decade, Chengda Pharmaceuticals Co's PS Ratio has ranged from 6.30 to 23.93. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #860 out of 955 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Chengda Pharmaceuticals Co's PS Ratio too high?
Chengda Pharmaceuticals Co's current PS Ratio of 12.53 is 14% above median its 10-year median of 11.01. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 23.93. The Drug Manufacturers industry median PS Ratio is 2.35. Chengda Pharmaceuticals Co's value of 12.53 is 433.2% above this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #860 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #860 out of 955 companies for PS Ratio. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 2.35. Chengda Pharmaceuticals Co's value of 12.53 is 433.2% above this benchmark. Historically, Chengda Pharmaceuticals Co's own PS Ratio has ranged from 6.30 to 23.93 over the past decade. While the company's 10-year median is 11.01 vs. the industry median of 2.35, Chengda Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current PS Ratio of 12.53 is 433.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current PS Ratio is 12.53, which is 14% above median its own 10-year median of 11.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥37.94 — trading 24.6% above its estimated fair value. The current PS Ratio is 12.53, which is 14% above median its 10-year median of 11.01 and 433.2% above the Drug Manufacturers industry median of 2.35. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current PS Ratio is 12.53 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥37.94 is trading 24.6% above its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SZSE:301201:
PS Ratio: 12.53 (14% above median its 10-year median of 11.01)
GF Value™: ¥30.45 vs. price of ¥37.94 (24.6% above fair value)
Industry Position: 433.2% above the Drug Manufacturers median (#860 of 955)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score
Get the complete analysis for SZSE:301201
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
